Epicardial fat, body mass index, and triglyceride are independent contributors of serum fibroblast growth factor 21 level in obese premenopausal women

Basit Öğe Kaydı
dc.contributor.authorAkyildiz, Z. I.
dc.contributor.authorPolat, S.
dc.contributor.authorYurekli, B. S.
dc.contributor.authorKocabas, G. U.
dc.contributor.authorTuluce, K.
dc.contributor.authorTuluce, S. Y.
dc.contributor.authorKocabas, U.
dc.contributor.authorBozkaya, G.
dc.contributor.authorYuksel, A.
dc.contributor.authorNazli, C.
dc.date.accessioned2019-10-27T22:27:55Z
dc.date.available2019-10-27T22:27:55Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose The hormone fibroblast growth factor 21 (FGF-21) regulates carbohydrate and lipid homeostasis. FGF-21 represents an attractive novel therapy for obesity since administration of FGF-21 has been shown to improve metabolic abnormalities in obese animal models. We investigated FGF-21 and its relationship with epicardial fat thickness (EFT), metabolic parameters, and inflammatory markers in premenopausal obese women compared to controls with similar Systematic Coronary Risk Evaluation (SCORE) project risk profiles. Methods Forty-five obese premenopausal women with body mass index (BMI) >= 30 kg/m(2) and 41 control premenopausal women with BMI <25 kg/m(2) with similar SCORE project risk profiles were included in this case-control study. EFT was evaluated by two-dimensional transthoracic echocardiography. Serum FGF-21 was measured with an ELISA kit. Results FGF-21 and EFT were significantly higher in obese women compared to controls (p < 0.001). Multiple stepwise linear regression analysis showed that EFT, BMI, and triglycerides (TG) independently contributed to FGF-21 (R-2 = 0.757, p < 0.001). However, homeostasis model assessment of insulin resistance (HOMA-IR), visceral ectopic fat, and inflammatory markers were not found as a direct contributor to serum FGF-21 level (p > 0.05). Conclusions EFT, BMI, and TG may play an important role in predicting serum FGF-21 level which may be a potential therapeutic target in cardiometabolic disorders in the future.en_US
dc.identifier.doi10.1007/s40618-014-0185-3en_US
dc.identifier.endpage366en_US
dc.identifier.issn0391-4097
dc.identifier.issn1720-8386
dc.identifier.issue3en_US
dc.identifier.pmid25312836en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage361en_US
dc.identifier.urihttps://doi.org/10.1007/s40618-014-0185-3
dc.identifier.urihttps://hdl.handle.net/11454/50799
dc.identifier.volume38en_US
dc.identifier.wosWOS:000350681200011en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Endocrinological Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEpicardial fat thicknessen_US
dc.subjectObesityen_US
dc.subjectPremenopauseen_US
dc.subjectFibroblast growth factor-21en_US
dc.titleEpicardial fat, body mass index, and triglyceride are independent contributors of serum fibroblast growth factor 21 level in obese premenopausal womenen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu